Chemistry:N-Desalkylflurazepam

From HandWiki
Revision as of 07:36, 8 February 2024 by JMinHep (talk | contribs) (over-write)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Short description: Benzodiazepine analog


N-Desalkylflurazepam
Desalkylflurazepam.svg
Desalkylflurazepam ball-and-stick model.png
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC15H10ClFN2O
Molar mass288.71 g·mol−1
3D model (JSmol)
Melting point205 to 206 °C (401 to 403 °F) [1]

N-Desalkylflurazepam (also known as norflurazepam) is a benzodiazepine analog and an active metabolite of several other benzodiazepine drugs including flurazepam,[2] flutoprazepam,[3] fludiazepam,[4] midazolam,[5] flutazolam,[6] quazepam,[7] and ethyl loflazepate.[8][9] It is long-acting, prone to accumulation, and binds unselectively to the various benzodiazepine receptor subtypes.[7] It has been sold as a designer drug from 2016 onward.[10]

References

  1. SciFinder record for CAS#2886-65-9
  2. "Rapid quantitation of flurazepam and its major metabolite, N-desalkylflurazepam, in human plasma by gas-liquid chromatography with electron-capture detection". Journal of Chromatography 222 (3): 491–5. March 1981. doi:10.1016/S0378-4347(00)84153-5. PMID 7228960. 
  3. "Pharmacokinetics of flutoprazepam, a novel benzodiazepine drug, in normal subjects". European Journal of Drug Metabolism and Pharmacokinetics 14 (4): 293–8. 1989. doi:10.1007/bf03190114. PMID 2633923. 
  4. Human Toxicology (1st ed.). Elsevier Science. December 1996. p. 43. 
  5. "Desalkylflurazepam found in patients' samples after high-dose midazolam treatment". Drug Testing and Analysis 5 (9–10): 745–7. 2013. doi:10.1002/dta.1484. PMID 23713025. 
  6. "A method for screening for various sedative-hypnotics in serum by liquid chromatography/single quadrupole mass spectrometry". Forensic Science International 157 (1): 57–70. February 2006. doi:10.1016/j.forsciint.2005.03.011. PMID 15869852. 
  7. 7.0 7.1 "Comparison of the effects of quazepam and triazolam on cognitive-neuromotor performance". Psychopharmacology 92 (4): 459–64. 1987. doi:10.1007/bf00176478. PMID 2888152. 
  8. "Pharmacokinetic modeling of ethyl loflazepate (Victan) and its main active metabolites". Annals of Biomedical Engineering 17 (6): 633–46. 1989. doi:10.1007/bf02367467. PMID 2574017. 
  9. "Determination of circulating ethyl loflazepate metabolites in the baboon by radio-high-performance liquid chromatography with injection of crude plasma samples: comparison with solvent extraction and thin-layer chromatography". Journal of Chromatography 342 (1): 159–65. July 1985. doi:10.1016/S0378-4347(00)84498-9. PMID 2864352. 
  10. "a and plasma protein binding values for benzodiazepines appearing as new psychoactive substances". Drug Testing and Analysis 10 (8): 1258–1269. March 2018. doi:10.1002/dta.2387. PMID 29582576. https://rke.abertay.ac.uk/files/14640409/Maskell_ExperimentalVersusTheoreticalLogD7.4_pKa_Accepted_2018.pdf.